I believe Nader has already stated that the goals set forth by the last annual board meeting by the board of directors was to tackle life saving as their goal and to trial Leronlimab for 10 different life saving indications each year with the most life saving ability. That’s a great goal!

If out of 65 indications we trialed the most important life saving ones first. They will bring the most revenue. Saving lives is big money in any indication we trial. Since we are going to grow our little company into a big pharmaceutical company now like Nader recently said. The sheer growth of trialing the live saving high revenue indications first should be explosive on the stock price over the next year or two. I only see good things the next 3-5 years also as we knock out one trial after another. We have great early potential but even long term potential is super bright also. Who knows... we could be the biggest pharmaceutical company ever on revenue and with one universal molecule for many indications. It’s must be like when penicillin first hit the market. It was great for many things and saved many many lives . We will have that impact with Leronlimab. Thanks to all of us investing in this drug. We will have essentially changed the world in our little way of helping save lives by believing and investing in something so incredible and helping this drug make its way to market to be used by the masses. We should all be proud of the small part we played by sticking with CYDY.